|
Mortality endpoints
|
Number of
|
Relative risk
|
Risk difference
|
|---|
|
Studies
|
Patients
|
Effect size (95% CI)
|
I2
|
Effect size (95% CI)
|
I2
|
|---|
|
Randomized controlled trials
a
| | | | | | |
|
ICU mortality
|
3
|
292
|
0.55 (0.24 to 1.25)
|
75%
|
−0.28 (−0.53 to −0.03)*
|
76%
|
|
Hospital mortality
|
2
|
201
|
0.49 (0.12 to 2.07)
|
77%
|
−0.26 (−0.65 to 0.13)
|
75%
|
|
60-day mortality
|
2
|
279
|
0.97 (0.75 to 1.26)
|
0%
|
−0.01 (−0.12 to 0.10)
|
0%
|
|
Cohort studies
| | | | | | |
|
ICU mortality
|
5
|
226
|
1.05 (0.74 to 1.49)
|
1%
|
Not calculable
|
-
|
|
Hospital mortality
|
4
|
317
|
1.00 (0.23 to 4.34)
|
75%
|
Not calculable
|
-
|
|
60-day mortality
|
2
|
264
|
1.30 (0.96 to 1.78)
|
0%
|
Not calculable
|
-
|
- aTrials testing preventive therapy of corticosteroids for acute respiratory distress syndrome (ARDS) were excluded. Some studies provided data on both short-term and longer-term mortality. For cohort studies, only pooled relative risk was provided because adjusted results were needed for data pooling *P-value <0.05.
